Compare Eli Lilly And Co (LLY) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Standard Lithium Ltd — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Standard Lithium Ltd trades at $1.58 (market cap $398.07M). The key difference: Eli Lilly And Co is far larger — about 2612.6× Standard Lithium Ltd's market cap, and Eli Lilly And Co pays a 0.59% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Standard Lithium Ltd for 23 Days on average.
| LLY | SLI | |
|---|---|---|
Market Cap | $1.04T | $398.07M |
Volume | 3,064,878 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $1.28K | $5.65 |
52-Week Low | $799.57 | $1.61 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $1.09T | $260.98M |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Standard Lithium (SLI) trades at $1.61, down 2.42% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company is pre-revenue with significant losses, reporting negative EBITDA of $50.53 million for 2025, but has made progress on its South West Arkansas lithium project, targeting a final investment decision by end of 2026. Analyst consensus is unanimously bullish with a $3.83 price target.
The investment case hinges on successful project execution and commercialization, offering substantial upside if milestones are met. Key risks include the capital-intensive nature of lithium production, execution delays, and reliance on future financing, with current cash flow sustained by financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
